Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, Lazzarin A, Castagna A; MODAt Study Group.
Galli L, et al.
J Antimicrob Chemother. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5.
J Antimicrob Chemother. 2016.
PMID: 26945711
Clinical Trial.
OBJECTIVES: To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically suppressed and treated with atazanavir/ritonavir monotherapy versus atazanavir/ritonavir triple therapy. METHODS: MODAt is a p …
OBJECTIVES: To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically …